 |
Justin Petrone is the editor of GenomeWeb's BioArray News and covers the microarray and biochip sector of the genomics market. E-mail Justin Petrone or follow his GenomeWeb Twitter account at @BioArrayNews. |
Analysts Say Affy Turnaround 'Remains on Track' after Firm Posts 3 Percent Rise in Q2 Revenues
August 07, 2012
Analysts Say Affy Turnaround 'Remains on Track' after Firm Posts 3 Percent Rise in Q2 Revenues
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- After 'Pivotal' 2012, Affy Looks to CytoScan, Axiom Genotyping Products to Drive Future Growth
February 5, 2013 / BioArray News - At JP Morgan, Affy Provides Update on Cyto FDA Submission, New Genotyping Products, Restructuring
January 15, 2013 / BioArray News - Analysts, Investors 'Troubled' as Affymetrix's Preliminary Q3 Revenues Miss Estimates
October 9, 2012 / BioArray News - Q&A: INMEGEN's Alfredo Hidalgo on Using Genomics to Address Mexico's Most Pressing Health Problems
May 21, 2013 / BioArray News - Despite Continued Genotyping Growth, Weak Expression Sales Force Affymetrix to Suspend Guidance
May 7, 2013 / BioArray News